Pharma Journalist 8947 posts 0 comments

MilliporeSigma and the Broad Institute of MIT and Harvard announced an agreement to offer non-exclusive licenses to CRISPR intellectual property (IP) under their respective control for…
Read More...

Mallinckrodt plc and Silence Therapeutics plc announced a collaboration that will allow the companies to develop and commercialize RNAi drug targets designed to inhibit or 'silence' the…
Read More...

"It is exciting news for MS patients in China that Gilenya has received fast approval. The approval of Gilenya and the upcoming regulatory review for Mayzent demonstrate our commitment…
Read More...

Results from the INMARK study, a randomised, double-blind clinical trial of Ofev (nintedanib) vs. placebo (12 weeks) followed by an open label period (40 weeks) in patients with…
Read More...

Astellas Pharma Inc. and Frequency Therapeutics, Inc. announced that they have entered into an exclusive license agreement to develop and commercialize Frequency’s regenerative…
Read More...

TraceLink Inc. announced a partnership with Excellis Health Solutions to provide local implementation services for TraceLink's Russia compliance solution, helping pharmaceutical…
Read More...

Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of cancer, and AUM Biosciences (AUM), a company focused on the development of…
Read More...

Amgen and Allergan plc announced that MVASI (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab), are…
Read More...

Quotient Sciences and global investment firm Permira announced that a company backed by the Permira Funds has signed a definitive agreement to acquire a majority stake in Quotient from…
Read More...

SMi Group reports: This year’s Biosimilars event will focus on forecasting future regulatory, commercial and legal challenges to advance biosimilars uptake With less than 2 months to…
Read More...